Evidence map›Paper›PMID 41410439›Full record

ArticleMicrobiology spectrum2026

First report of an

Yi-Yu Lyu, Jie-Hao Tai, Cui-Ying Guo, Yin-Yin Zhang, Yao Chen, Qiang Zhou, Wen-Wen Chu, Yi-Le Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genetic and Phenotypic Characterization of aAntibiotics (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi-Yu Lyu *Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jie-Hao Tai *Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Cui-Ying GuoDepartment of Hospital Infection Prevention and Control, the First People's Hospital of Bengbu, Bengbu, Anhui, China.
Yin-Yin ZhangDepartment of Clinical Laboratory, the First People's Hospital of Bengbu, Bengbu, Anhui, China.
Yao ChenDepartment of Critical Care Medicine, the First People's Hospital of Bengbu, Bengbu, Anhui, China.
Qiang ZhouDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Wen-Wen ChuDepartment of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0002-0110-806X
Yi-Le WuDepartment of Hospital Infection Prevention and Control, the Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0003-0153-4904

Funding

National Natural Science Foundation of China 82202572Natural science research project funding of higher education institutions of Anhui province 2023AH053175
6 · The paper itself

Abstract

In carbapenem-resistant IMPORTANCE: Antimicrobial resistance has become a serious global public health concern, severely limiting therapeutic options. The global proliferation of carbapenem-resistant

Indexed as

beta-LactamasesEscherichia coliEscherichia coli InfectionsPlasmidsAnti-Bacterial AgentsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsChinaDrug Resistance, Multiple, BacterialEscherichia coli ProteinsHumansMicrobial Sensitivity TestsWhole Genome SequencingAnti-Bacterial Agentsbeta-lactamase KPC-2beta-LactamasesCarbapenemsEscherichia coli ProteinsblaKPC-2blaNDM-13Escherichia coliIncB/O/K/ZIS1294

Identifiers

PMID41410439
PMCPMC12889035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.